Pinned Tweet
Please check out this review of Emerging Tumor Agnostic Biomarkers!
Grateful to have had @AliSchram as a mentor. I learned a lot from her insights as a PI on numerous clinical trials in the Early Drug Development clinic @MSKCancerCenter!
Featured today by @MSKLibrary: Emerging Tumor-Agnostic Molecular Targets
#CancerResearch #TumorAgnosticTherapies
#PrecisionMedicine #MolecularTargets
#TargetedTherapies #OncologyBreakthroughs
#FutureOfCancerCare #InnovativeMedicine
#EmergingTherapies #CancerAwareness
#HopeThroughScience
@drdedipya @AliSchram
dx.doi.org/10.1158/1535-7163…
3
934
Dedipya Bhamidipati retweeted
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With #ProstateCancer. Co-authored by @drdedipya, and @thewonkologist.
Read the full article. brnw.ch/21wXFW7
#pcsm
So happy to share that one of my publications came out in JCO yesterday!
➡️ascopubs.org/doi/10.1200/OP-…
I am grateful to @TheWonkologist for giving me this opportunity to shed a light on BMA overuse and underuse in mCSPC and MCRPC respectively!
59
Dedipya Bhamidipati retweeted
Replying to @hsafaMD
Excited to be applying to #HemeOnc fellowship this cycle!
I’m Dedipya Bhamidipati—IM chief resident!
Excited to connect with programs & applicants!
📄 AAMC ID: 15373622
#MedTwitter #Fellowship2026 #Oncology #Hematology
Dedipya Bhamidipati retweeted
BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112
De-escalation of ICI therapy in NSCLC through either a) lower dosing regiments, b) decreased frequency of administration or c) fixed duration of therapy. The economic benefits would revolutionize antibody use! Such a valuable read @JordiRemon and @BenjaminBesseMD!
1
1
133
Establishing nivo/AVD in elderly patients with classic Hodgkin’s lymphoma would transform the care of patients suffering from cHL above the age of 60 years! Congratulations @PallawiTorkaMD @PaolaGhione_MD @SantoshVardhana!! So blessed to have worked with you!
Learned a lot from Dr. Salles during my elective in Lymphoma clinics over the past month. I got to see very interesting patients, with even more exciting treatment plans! @MSKCancerCenter truly harbors the most insightful teachers. Thankful to @Efrat_Luttwak for this rotation!!!
Dedipya Bhamidipati retweeted
Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led to recent FDA approval in lung and pancreatic cancer. RNA seq is critical to identify these fusions. 🧬@NEJM pubmed.ncbi.nlm.nih.gov/3990…
When you’re watching your Lymphoma attending casually drop ASH updates during your heme elective at the VA! Perfect timing!
Thank you @OncBrothers @TargetedOnc for the opportunity to share my thoughts.
We discuss high impact #lymphoma abstracts from #ASH24 @ASH_hematology and my take on how they impact care of patients with lymphoma.
Do give a listen.
#lymsm @MSKCancerCenter @MSK_DeptOfMed
1
241
Dedipya Bhamidipati retweeted
Cancer statistics- 2025
👀
Some 🫁 cancer observations:
1. Continued nice decrease in LC incidence/death rates
2. BUT probably 1st time in history of cancer stats- more cases in women than men
3. AND finally we no longer can say - “lung cancer causes more deaths than prostate/breast/colon cancer combined”- amazing progress💪👏🎉
(Lung cancer- 124730- colon/breast/prostate- 130840)
acsjournals.onlinelibrary.wi…
Dedipya Bhamidipati retweeted
Cancer Chemotherapy
@Cancer_Cell
Dedipya Bhamidipati retweeted
Adjuvant IO trials in muscle-invasive urothelial carcinoma:
IMvigor010: Atezo DFS HR 0.89, OS HR 0.85.
CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76.
AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98.
#oncology #cancer #urothelialcarcinoma @OncoAlert @MattGalsky @tompowles1 @apolo_andrea @Uromigos
Dedipya Bhamidipati retweeted
ADCs are among the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved and >200 in active development.
Here’s 10 facts to know to prepare for the rise of ADCs🧵
Dedipya Bhamidipati retweeted
Summary of the FDA-approved tumor agnostic drugs #esmo24 #precisionmedicine
Dedipya Bhamidipati retweeted
TROPHY-U-01 Cohort 2:
Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%).
#cancer #oncology @OncoAlert
@DrScottTagawa @cnsternberg @y_loriot @neerajaiims @CParkMD @PGrivasMDPhD
Dedipya Bhamidipati retweeted
Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging. ja.ma/4fAaPDY @KAhmedMD @MoffittNews
Dedipya Bhamidipati retweeted
It truly breaks my heart to see patients in my clinic who come to the office hoping for a “cure” when there isn’t one. I know I’m not saying something that hasn’t been said before, but we need to do so so much more for patients with pancreatic cancer. This cancer sucks so much! 😕
It feels unfair and devastating to discuss prognosis with patients who have stage IV pancreatic cancer. How could one pack all their lives/love/laughter/family/vacation/hobbies in a few months to a year (on top of all the terrible side effects from chemo)?
Many of these were healthy with no major problems, living active and healthy lives. I’m hopeful we will have some major breakthroughs in this disease in the years to come so we can help our patients have so much more time with their loved ones. #pancreaticcancer
Fun fact to share from this rotation which I was unaware of: filgrastim/peg-filgrastim should not be used in patients with sickle cell disease (consideration came up for neutropenic fever in this case), as it serves as another form of stressor which can precipitate pain crisis!
110
Loving every second of the 2nd week of inpatient lymphoma rotation at @MSKCancerCenter. Learning so much, and seeing such rare pathologies has been so enlightening. And all the TLS monitoring too 🤣
2
283


























